NIFTY  8,417.00  0.23%
  SENSEX  27,257.60  0.08%
 CURRENCY  Rs  67.96/$ 72.70/€, 83.99/£
  GOLD  28,732.00  -0.02%
  SILVER  41,610.00  0.03%
  DAX  11,540.00  -0.13%
  FTSE  7,220.38  -1.46%
  CAC  4,859.69  -0.40%
  HANG SENG  23,098.30  1.13%
  NIKKEI  18,894.40  0.43%
  Shanghai Composite  3,113.01  0.08%
  DOW JONES  19,826.80  -0.30%
  NASDAQ  5,538.73  -0.63%
  S&P 500  2,267.89  -0.30%
BREAKING NEWS - NCLT DISMISSES MISTRY'S CONTEMPT PETITION BREAKING NEWS - COMPANY LAW TRIBUNAL DISMISSES MISTRY'S CONTEMPT PLEA VS TATA SONS

U.S. FDA Relief For Ranbaxy

Video:

Play this video

March 28: Bloomberg reports that the U.S. FDA has disputed a study of generic heart drugs by Preston Mason. The regulator said generics from overseas are safe, as it did not find contaminants in samples obtained through retail pharmacies. The stock of Ranbaxy today took heart from that news and shot up by 4% in intraday trade. Priya Sheth shares a detailed report on the same.